Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Loading
Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions.
| Analyst | Firm | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Matt Larew | William Blair | 14 questions · 14% challenging |
| Puneet Souda | Leerink Partners | 14 questions · 21% challenging |
| Dan Leonard | RBC Capital Markets | 12 questions · 8% challenging |
| Patrick Donnelly | Citigroup | 11 questions · 0% challenging |
| Dan Arias | Stifel | 9 questions · 11% challenging |
| Daniel Markowitz | Evercore ISI | 7 questions · 14% challenging |
| Kyle Boucher | TD Cowen | 6 questions · 0% challenging |
| Sung Nam | Scotiabank | 6 questions · 0% challenging |
| Mac Etoch | Stephens | 5 questions · 0% challenging |
| Justin Bowers | Deutsche Bank | 4 questions · 0% challenging |
| Firm | Analysts | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Leerink Partners | 1 analyst | 14 questions · 21% challenging |
| William Blair | 1 analyst | 14 questions · 14% challenging |
| RBC Capital Markets | 2 analysts | 14 questions · 7% challenging |
| Citigroup | 1 analyst | 11 questions · 0% challenging |
| Stifel | 1 analyst | 9 questions · 11% challenging |
| Evercore ISI | 1 analyst | 7 questions · 14% challenging |
| Stephens | 2 analysts | 7 questions · 0% challenging |
| TD Cowen | 1 analyst | 6 questions · 0% challenging |
Bio-Techne delivered flat organic revenue of $295.9 million as FDA Fast Track timing from two large cell therapy customers created a 400 basis point headwind, masking 4% underlying growth. GMP reagents declined 50% on the customer-specific air pocket, but the remaining customer base grew nearly 30%, and proteomic analysis instruments grew upper single digits led by continued LEO adoption. COMET spatial biology bookings accelerated nearly 40% for the second consecutive quarter while China delivered mid-single digit growth for a third straight quarter. Adjusted operating margin expanded 100 basis points to 31.1% as the company maintained full-year guidance for low single digit growth and 100bp margin expansion.
Demand | Revenue Growth | Guidance Reliability | Margin | Macroeconomic | Product Launch | Cost Pressure | M&A | |
|---|---|---|---|---|---|---|---|---|
| 2025Q1 | 8 | 6 | 1 | 1 | 2 | 5 | 1 | 1 |
| 2025Q2 | 7 | 6 | 1 | 3 | 3 | 1 | 1 | 2 |
| 2025Q3 | 6 | 5 | 3 | 2 | 2 | 2 | 1 | |
| 2025Q4 | 8 | 5 | 5 | 3 | 5 | 2 | 2 | |
| 2026Q1 | 9 | 10 | 4 | 3 | 1 | 1 | 1 | |
| 2026Q2 | 7 | 4 | 2 | 3 | 2 | 2 | 3 | 1 |
| '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | '26Q2 | |
|---|---|---|---|---|---|---|
| Demand | 8 | 7 | 6 | 8 | 9 | 7 |
| Revenue Growth | 6 | 6 | 5 | 5 | 10 | 4 |
| Guidance Reliability | 1 | 1 | 3 | 5 | 4 | 2 |
| Margin | 1 | 3 | 2 | 3 | 3 | 3 |
| Macroeconomic | 2 | 3 | 2 | 5 | 1 | 2 |
| Product Launch | 5 | 1 | 2 | 2 | ||
| Cost Pressure | 1 | 1 | 2 | 1 | 3 | |
| M&A | 1 | 2 | 1 | 2 | 1 | 1 |
What TECH and other companies said about each other on FY2026 Q2 earnings calls — extracted verbatim from public transcripts. Mentions from the newest quarter are a Pro feature.
“We currently own 20% of Wilson Wolf and will complete the full acquisition by the end of calendar year 2027 or sooner based upon achievement of certain milestones.”
Bio-Techne owns 20% of Wilson Wolf (G-Rex bioreactors) and will complete the full acquisition by end of 2027; Wilson Wolf grew 20% and carries 70%+ EBITDA margins, an M&A signal on the target.
No 8-K events recorded for this window.
The table scrolls sideways. Swipe it, or select it and use the arrow keys.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2025 Q1 | $289M | +4.5% | $0.21 | -32.3% | 63.2% | 13.8% | 11.6% | $55M |
| FY2025 Q2 | $297M | +9.0% | $0.22 | +29.4% | 65.3% | 16.0% | 11.7% | $78M |
| FY2025 Q3 | $316M | +4.2% | $0.14 | -54.8% | 67.9% | 12.2% | 7.1% | $31M |
| FY2025 Q4 | $317M | +3.5% | $-0.11 | -144.0% | 62.7% | -7.5% | -5.6% | $93M |
| FY2026 Q1 | $287M | -1.0% | $0.24 | +14.3% | 65.6% | 16.6% | 13.3% | $22M |
| FY2026 Q2Selected | $296M | -0.4% | $0.24 | +9.1% | 64.6% | 18.4% | 12.8% | $76M |
| FY2026 Q3 | $311M | -1.5% | $0.32 | +128.6% | 66.9% | 24.2% | 16.4% | $78M |
| FY2026 Q4 | $321M | +1.3% | $0.36 | +427.3% | 65.8% | 23.1% | 17.0% | $87M |
Management’s own words, often on a non-GAAP, constant-currency, or adjusted basis — so these can differ from the GAAP figures above (e.g. constant-currency revenue growth excludes currency swings).
Calendar quarter Q4 2025Earnings call Feb 4, 2026
FY2026 Q2 in brief
Bio-Techne delivered flat organic revenue of $295.9 million as FDA Fast Track timing from two large cell therapy customers created a 400 basis point headwind, masking 4% underlying growth.
Newest quarter FY2026 Q3 is part of Pro · see what Pro adds →
Sources. Tellvest earnings-call sentiment score for Bio-Techne (TECH), FY2026 Q2: 6/10. Scores: Bio-Techne’s public earnings-call transcripts and SEC-reported results — the base band is anchored to reported GAAP revenue growth; transcript, EPS and guidance adjustments are applied separately (documented exceptions apply to a few issuers). Price: TECH daily closing prices for the trailing year; dots mark earnings calls, colored by that quarter’s score; the newest quarter’s score is part of Tellvest Pro. How to read a company earnings-call score.
GAAP revenue YoY -0.39% → base 5. The base score is anchored to the GAAP revenue YoY band before transcript, EPS, and guidance adjustments.
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
TECH Bio-Techne | 6 | -0.4% | |
| ALNY Alnylam Pharmaceuticals | 9 | +85.0% | |
| INCY Incyte | 9 | +27.8% | |
| INSM Insmed Incorporated | 9 | +152.6% | |
| MRNA Moderna | 3 | -29.1% | |
| REGN Regeneron Pharmaceuticals | 4 | +2.5% | |
| VRTX Vertex Pharmaceuticals | 9 | +10.8% |